XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.19.2

License Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
Jan. 09, 2018 | Nov. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018
License Agreements [Line Items] |  |  |  |  |  |
Cost of product revenues |  |  | $ 48,654 | $ 46,838 | $ 97,818 | $ 89,944
Annual net sales |  |  | $ 75,040 | $ 73,061 | $ 149,556 | $ 136,810
Exercise price of warrant |  | $ 19.20 |  |  |  |
Nucynta Commercialization Agreement | Assertio |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Cost of product revenues | $ 10,000 |  |  |  |  |
Annual net sales | 135,000 |  |  |  |  |
Nucynta Commercialization Agreement | Nucynta | Assertio |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Payment for inventory | 6,223 |  |  |  |  |
Reimbursement for prepaid expenses | 1,987 |  |  |  |  |
Liability relating to sales | 22,660 |  |  |  |  |
Variable royalty payment based on net sales | 233,000 |  |  |  |  |
Quarterly royalty payable | $ 33,750 |  |  |  |  |
Nucynta Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 1 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales on and after January 1, 2022 |  | 58.00% |  |  |  |
Nucynta Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 2 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales on and after January 1, 2022 |  | 25.00% |  |  |  |
Nucynta Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 3 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales on and after January 1, 2022 |  | 17.50% |  |  |  |
Royalty payment limit on and after January 1, 2022 |  | $ 258,000 |  |  |  |
Nucynta Commercialization Agreement | Nucynta | Assertio | Minimum | Sales Royalty Structure 2 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit on and after January 1, 2022 |  | 233,000 |  |  |  |
Nucynta Commercialization Agreement | Nucynta | Assertio | Maximum | Sales Royalty Structure 1 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit on and after January 1, 2022 |  | 233,000 |  |  |  |
Nucynta Commercialization Agreement | Nucynta | Assertio | Maximum | Sales Royalty Structure 2 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit on and after January 1, 2022 |  | $ 258,000 |  |  |  |
Third Amendment to the Commercialization Agreement |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Number of shares that can be purchased |  | 1,041,667 |  |  |  |
Exercise price of warrant |  | $ 19.20 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Minimum royalty payment eliminated |  | $ 135,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Maximum | Any 12-month period through January 1, 2022 |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Net sales limit upon which Counterparty can terminate without penalty |  | 180,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Maximum | Any 12-month period commencing on January 1, 2022 |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Net sales limit upon which Counterparty can terminate without penalty |  | 170,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Termination fee owed if Company terminates |  | $ 5,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 1 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales between January 1, 2019 and December 31, 2021 |  | 65.00% |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | $ 180,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 2 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales between January 1, 2019 and December 31, 2021 |  | 14.00% |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 3 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales between January 1, 2019 and December 31, 2021 |  | 58.00% |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 4 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales between January 1, 2019 and December 31, 2021 |  | 20.00% |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Sales Royalty Structure 5 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment as percentage of annual net sales between January 1, 2019 and December 31, 2021 |  | 15.00% |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Minimum | Sales Royalty Structure 2 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | $ 180,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Minimum | Sales Royalty Structure 3 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 210,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Minimum | Sales Royalty Structure 4 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 233,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Minimum | Sales Royalty Structure 5 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 258,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Minimum | Sales Royalty Structure 6 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Sales threshold where supplemental royalty payment is due |  | $ 180,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Maximum |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Percentage of supplemental royalty based on net sales |  | 4.90% |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Maximum | Sales Royalty Structure 2 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | $ 210,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Maximum | Sales Royalty Structure 3 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 233,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Maximum | Sales Royalty Structure 4 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 258,000 |  |  |  |
Third Amendment to the Commercialization Agreement | Nucynta | Assertio | Maximum | Sales Royalty Structure 6 [member] |  |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |  |
Sales threshold where supplemental royalty payment is due |  | $ 243,000 |  |  |  |

X
- Definition Collaborative Arrangement, Minimum Royalty Payment Eliminated + References No definition available. + Details
Name: | coll_CollaborativeArrangementMinimumRoyaltyPaymentEliminated
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of supplemental royalty based on net sales. + References No definition available. + Details
Name: | coll_CollaborativeArrangementPercentageOfSupplementalRoyaltyPaymentBasedOnNetSales
Namespace Prefix: | coll_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty payment as percentage of annual net sales. + References No definition available. + Details
Name: | coll_CollaborativeArrangementRoyaltyPaymentAsPercentageOfAnnualNetSales
Namespace Prefix: | coll_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty payment as percentage of annual net sales after specific period. + References No definition available. + Details
Name: | coll_CollaborativeArrangementRoyaltyPaymentAsPercentageOfAnnualNetSalesAfterSpecificPeriod
Namespace Prefix: | coll_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Royalty Payment Limit + References No definition available. + Details
Name: | coll_CollaborativeArrangementRoyaltyPaymentLimit
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Royalty Payment Limit After Specific Period + References No definition available. + Details
Name: | coll_CollaborativeArrangementRoyaltyPaymentLimitAfterSpecificPeriod
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Supplemental Royalty Payment Based on Net Sales + References No definition available. + Details
Name: | coll_CollaborativeArrangementSupplementalRoyaltyPaymentBasedOnNetSales
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Termination Fee + References No definition available. + Details
Name: | coll_CollaborativeArrangementTerminationFee
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreements [Line Items] + References No definition available. + Details
Name: | coll_LicenseAgreementsLineItems
Namespace Prefix: | coll_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of minimum royalty should be paid for each quarter. + References No definition available. + Details
Name: | coll_MinimumQuarterlyRoyaltyPaymentsLiability
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Net Sales Threshold Upon Which Counterparty can Terminate Without Penalty + References No definition available. + Details
Name: | coll_NetSalesThresholdUponWhichCounterpartyCanTerminateWithoutPenalty
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of cash transferred for inventory as per agreement. + References No definition available. + Details
Name: | coll_PaymentForInventory
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of prepaid expenses reimbursed. + References No definition available. + Details
Name: | coll_PaymentOfReimbursementForPrepaidExpenses
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales threshold where supplemental royalty payment is due + References No definition available. + Details
Name: | coll_SalesThresholdWhereSupplementalRoyaltyPaymentIsDue
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 55 -Paragraph 27 -URI http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046 + Details
Name: | us-gaap_ContractWithCustomerRefundLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coll_NucyntaCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=coll_AssertioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=coll_NucyntaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coll_ThirdAmendmentToCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_CommencementScenario1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_CommencementScenario2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure5Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure6Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |